RBC Capital Reiterates Sector Perform on Regeneron Pharmaceuticals, Maintains $816 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams reiterates a Sector Perform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintains an $816 price target.
June 27, 2023 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital reiterates a Sector Perform rating on Regeneron Pharmaceuticals and maintains an $816 price target.
The news is directly related to Regeneron Pharmaceuticals as RBC Capital reiterates its Sector Perform rating and maintains the $816 price target. This reaffirms the analyst's neutral stance on the stock, which may not have a significant short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100